US stocks rally as Powell hints at possible rate cuts
26 Aug 2024 - US stocks rallied on Friday after Federal Reserve Chair Jerome Powell hinted that interest rate cuts could be on the horizon.
26Aug
23Aug
Stocks of the Hour: Proteomics International Laboratories, Aurumin, Forrestania Resources
23 Aug 2024 - A snapshot of the stocks on the move, featuring Proteomics International Laboratories (ASX:PIQ), Aurumin (ASX:AUN) and Forrestania Resources (ASX:FRS).
23Aug
S&P 500 stumbles ahead of Jackson Hole
23 Aug 2024 - The S&P 500 experienced a pullback overnight as investors anticipated Federal Reserve Chair Jerome Powell's keynote address at the Jackson Hole Economic Symposium.
22Aug
Stocks of the Hour: Australasian Metals, Critical Resources, First Lithium
22 Aug 2024 - A snapshot of the stocks on the move, featuring Australasian Metals (ASX:A8G), Critical Resources (ASX:CRR) and First Lithium (ASX:FL1).
22Aug
S&P 500 rallies on Fed minutes
22 Aug 2024 - The S&P 500 surged on Wednesday, fuelled by optimism that the Federal Reserve will lower interest rates at its upcoming meeting.
21Aug
Stocks of the Hour: Dundas Minerals, Antilles Gold, MTM Critical Metals
21 Aug 2024 - A snapshot of the stocks on the move, featuring Dundas Minerals (ASX:DUN), Antilles Gold (ASX:AAU, OTCQB:ANTMF) and MTM Critical Metals (ASX:MTM).
21Aug
US markets takes a breather after strong rally
21 Aug 2024 - The US market's recent rally hit a snag overnight as stocks retreated, ending a winning streak.
20Aug
Stocks of the Hour: Corella Resources, Green Technology Metals, Lithium Universe
20 Aug 2024 - A snapshot of the stocks on the move, featuring Corella Resources (ASX:CR9), Green Technology Metals (ASX:GT1) and Lithium Universe (ASX:LU7).
20Aug
Wall Street rallies ahead of Jackson Hole meeting
20 Aug 2024 - US shares advanced on Monday, extending recent gains as investors looked ahead to the highly anticipated Federal Reserve symposium later this week.
19Aug
Immutep (ASX:IMM) reports first subject dosed in autoimmune disease study
19 Aug 2024 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses progress with the company's IMP761 drug, which is potentially active in more than 90% of autoimmune diseases.